Oxaliplatino [Spanish]
Categoria
Oxaliplatino [Spanish] Nombres de marca, Oxaliplatino [Spanish] Analogos
Oxaliplatino [Spanish] Marca los nombres de mezcla
Oxaliplatino [Spanish] Formula quimica
Oxaliplatino [Spanish] RX enlace
Oxaliplatino [Spanish] FDA hoja
Oxaliplatino [Spanish] MSDS (hoja de seguridad de materiales)
Oxaliplatino [Spanish] Sintesis de referencia
Oxaliplatino [Spanish] Peso molecular
Oxaliplatino [Spanish] Punto de fusion
Oxaliplatino [Spanish] H2O Solubilidad
Oxaliplatino [Spanish] Estado
Oxaliplatino [Spanish] LogP
Oxaliplatino [Spanish] Formas de dosificacion
Oxaliplatino [Spanish] Indicacion
Oxaliplatino [Spanish] Farmacologia
Oxaliplatino [Spanish] Absorcion
Oxaliplatino [Spanish] Toxicidad
Oxaliplatino [Spanish] Informacion de Pacientes
Patients and patientsí caregivers should be informed of the expected side effects of ELOXATIN, particularly its neurologic effects, both the acute, reversible effects, and the persistent neurosensory toxicity. Patients should be informed that the acute neurosensory toxicity may be precipitated or exacerbated by exposure to cold or cold objects. Patients should be instructed to avoid cold drinks, use of ice, and should cover exposed skin prior to exposure to cold temperature or cold objects.
Patients must be adequately informed of the risk of low blood cell counts and instructed to contact their physician immediately should fever, particularly if associated with persistent diarrhea, or evidence of infection develop.
Patients should be instructed to contact their physician if persistent vomiting, diarrhea, signs of dehydration, cough or breathing difficulties occur, or signs of allergic reaction appear.
![Oxaliplatino_[Spanish]](/images/rx/APRD00186.gif)
